Drawing for AVALONRX

USPTO serial 76352378

AVALONRX

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
FINK, GINA M
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with AVALONRX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael T. Murphy

MICHAEL T MURPHY BELL, BOYD & LLOYD LLCPO BOX 1135CHICAGO, IL 60690-1135UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005LINE OF ANTI-CANCER AGENTS AND PREPARATIONSACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Sep 28, 2005MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 28, 2005ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 3, 2005EX3GSOU EXTENSION 3 GRANTED—
Dec 16, 2004EXT3SOU EXTENSION 3 FILED—
Dec 16, 2004EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 30, 2004EX2GSOU EXTENSION 2 GRANTED—
Jul 12, 2004CFITCASE FILE IN TICRS—
Jun 30, 2004EXT2SOU EXTENSION 2 FILED—
Jun 30, 2004EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 21, 2004TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 22, 2004EX1GSOU EXTENSION 1 GRANTED—
Dec 31, 2003EXT1SOU EXTENSION 1 FILED—
Dec 31, 2003EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 1, 2003NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 18, 2002ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Jun 25, 2002PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 5, 2002NPUBNOTICE OF PUBLICATION—
Apr 8, 2002CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 26, 2002DOCKASSIGNED TO EXAMINER—
Mar 13, 2002DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance